JP2010532764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532764A5 JP2010532764A5 JP2010515288A JP2010515288A JP2010532764A5 JP 2010532764 A5 JP2010532764 A5 JP 2010532764A5 JP 2010515288 A JP2010515288 A JP 2010515288A JP 2010515288 A JP2010515288 A JP 2010515288A JP 2010532764 A5 JP2010532764 A5 JP 2010532764A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- specific binding
- binding protein
- domain
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009870 specific binding Effects 0.000 claims 34
- 102000023732 binding proteins Human genes 0.000 claims 27
- 108091008324 binding proteins Proteins 0.000 claims 27
- 208000011380 COVID-19–associated multisystem inflammatory syndrome in children Diseases 0.000 claims 11
- 238000002319 photoionisation mass spectrometry Methods 0.000 claims 11
- 235000018102 proteins Nutrition 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102220288073 rs151218932 Human genes 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94839707P | 2007-07-06 | 2007-07-06 | |
| PCT/US2008/069378 WO2009023386A2 (en) | 2007-07-06 | 2008-07-07 | Binding peptides having a c-terminally disposed specific binding domain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010532764A JP2010532764A (ja) | 2010-10-14 |
| JP2010532764A5 true JP2010532764A5 (enExample) | 2011-08-25 |
Family
ID=40351400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515288A Pending JP2010532764A (ja) | 2007-07-06 | 2008-07-07 | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090148447A1 (enExample) |
| EP (1) | EP2167130A2 (enExample) |
| JP (1) | JP2010532764A (enExample) |
| CN (1) | CN101990439A (enExample) |
| AU (1) | AU2008287195A1 (enExample) |
| BR (1) | BRPI0814060A2 (enExample) |
| CA (1) | CA2691819A1 (enExample) |
| WO (1) | WO2009023386A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| US8409577B2 (en) * | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| WO2009040562A1 (en) | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| MX340204B (es) * | 2008-04-11 | 2016-06-30 | Emergent Product Dev Seattle | Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo. |
| KR20110044992A (ko) * | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| BRPI0920749A8 (pt) | 2008-10-02 | 2017-12-12 | Emergent Product Dev Seattle | Proteínas de ligação de antagonista multialvo cd86 |
| CN105218673A (zh) * | 2008-10-10 | 2016-01-06 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
| MX341084B (es) | 2009-11-02 | 2016-08-05 | Univ Washington | Composiciones de nucleasas terapéuticas y métodos. |
| US20130052195A1 (en) | 2009-12-23 | 2013-02-28 | Emergent Product Development Seattle,LLC | Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof |
| CN103124743A (zh) | 2009-12-29 | 2013-05-29 | 新兴产品开发西雅图有限公司 | Ron结合构建物及其使用方法 |
| PL2544719T3 (pl) * | 2010-03-12 | 2020-01-31 | Debiopharm International S.A. | Cząsteczki wiążące cd37 i ich immunokoniugaty |
| SI3333265T1 (sl) | 2010-05-14 | 2020-08-31 | Oregon Health & Science University | Rekombinantni HCMV in RHCMV vektorji, ki kodirajo heterologni antigen izoliran iz virusa hepatitisa B virus in njihove uporabe |
| PH12012502272A1 (en) | 2010-05-20 | 2017-07-26 | Ablynx Nv | Biological materials related to her3 |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| CN101912599A (zh) * | 2010-07-30 | 2010-12-15 | 北京凯因科技股份有限公司 | 重组人白介素15在治疗恶性腹水瘤药物中的应用 |
| CA2817015A1 (en) * | 2010-11-09 | 2012-05-18 | Altimab Therapeutics, Inc. | Protein complexes for antigen binding and methods of use |
| MX2013011385A (es) | 2011-04-01 | 2014-03-13 | Immunogen Inc | Moleculas de union a cd37 y sus inmunoconjugados. |
| PE20141172A1 (es) * | 2011-04-29 | 2014-09-22 | Univ Washington | Composiciones de nucleasa terapeuticas y metodos |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| LT2691530T (lt) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glikoproteinai ir rekombinantiniai vektoriai |
| US20130068691A1 (en) * | 2011-08-05 | 2013-03-21 | Henry John Smith | Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders |
| DK2828292T3 (da) | 2012-03-20 | 2019-01-02 | Biogen Ma Inc | Jcv-neutraliserende antistoffer |
| PT2828284T (pt) | 2012-03-20 | 2019-06-17 | Biogen Ma Inc | Jcv neutralizando anticorpos |
| CA2870545A1 (en) | 2012-04-20 | 2013-10-24 | Emergent Product Development Seattle, Llc | Cd3 binding polypeptides |
| JP2015517511A (ja) | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| WO2015066550A1 (en) | 2013-10-31 | 2015-05-07 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| CN107002048B (zh) | 2014-07-16 | 2021-07-06 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| WO2016200676A1 (en) | 2015-06-08 | 2016-12-15 | Immunogen, Inc. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
| JP6890581B2 (ja) | 2015-08-28 | 2021-06-18 | デビオファーム インターナショナル， エス． アー． | Ｃｄ３７の検出のための抗体およびアッセイ |
| JP7002446B2 (ja) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| CN109790526A (zh) | 2016-07-01 | 2019-05-21 | 分解治疗有限责任公司 | 优化的二核酸酶融合体和方法 |
| MX2019004518A (es) | 2016-10-18 | 2019-06-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e. |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| US11578115B2 (en) | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| AU2018236450A1 (en) | 2017-03-16 | 2019-10-03 | The General Hospital Corporation | Chimeric antigen receptors targeting CD37 |
| KR102777015B1 (ko) | 2017-08-22 | 2025-03-10 | 사나바이오, 엘엘씨 | 가용성 인터페론 수용체 및 그의 용도 |
| AU2019277836A1 (en) | 2018-05-30 | 2021-01-21 | Debiopharm International, S.A. | Anti-CD37 immunoconjugate dosing regimens |
| JP7611705B2 (ja) * | 2018-06-22 | 2025-01-10 | ザ ジェネラル ホスピタル コーポレイション | Ｃｄ３７及びｃｄ１９を標的とするキメラ抗原受容体 |
| WO2021030488A1 (en) | 2019-08-12 | 2021-02-18 | Bienvenue David Leonard | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| WO2022104692A1 (en) * | 2020-11-20 | 2022-05-27 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Engineered antibody, antibody-drug conjugate, and use thereof |
| US20240301086A1 (en) | 2020-12-01 | 2024-09-12 | Aptevo Research And Development Llc | Tumor-associated antigens and cd3-binding proteins, related compositions, and methods |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4444744A (en) * | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4818709A (en) * | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
| US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| GB8508845D0 (en) * | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US4932412A (en) * | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5217713A (en) * | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
| DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5897861A (en) * | 1989-06-29 | 1999-04-27 | Medarex, Inc. | Bispecific reagents for AIDS therapy |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
| US5023263A (en) * | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
| US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| DK0617706T3 (da) * | 1991-11-25 | 2001-11-12 | Enzon Inc | Multivalente antigenbindende proteiner |
| DK1024191T3 (da) * | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
| US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5480989A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5411967A (en) * | 1992-10-13 | 1995-05-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5480988A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5504091A (en) * | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
| WO1995009917A1 (en) * | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| US5385909A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
| US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
| US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| US5389639A (en) * | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
| US6380369B1 (en) * | 1994-01-27 | 2002-04-30 | Human Genome Sciences, Inc. | Human DNA mismatch repair proteins |
| US5945273A (en) * | 1997-06-03 | 1999-08-31 | Human Genome Sciences, Inc. | Human oxalyl-coa decarboxylase |
| US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| DE59508945D1 (de) * | 1994-08-26 | 2001-02-08 | Aventis Pharma Gmbh | Gentherapie von erkrankungen, die durch das immunsystem bedingt sind, mit hilfe eines zellspezifischen zellzyklusregulierten wirkstoffes |
| US6380169B1 (en) * | 1994-08-31 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Metal complex containing oligonucleoside cleavage compounds and therapies |
| US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
| US6383814B1 (en) * | 1994-12-09 | 2002-05-07 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5866330A (en) * | 1995-09-12 | 1999-02-02 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US6379966B2 (en) * | 1999-02-26 | 2002-04-30 | Mirus Corporation | Intravascular delivery of non-viral nucleic acid |
| DE19613691A1 (de) * | 1996-04-05 | 1997-10-09 | Boehringer Ingelheim Int | Arzneimittel für die Behandlung von Tumorerkrankungen |
| US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5846948A (en) * | 1996-08-30 | 1998-12-08 | Arch Development Corporation | Herpes simplex virus ORF P is a repressor of viral protein synthesis |
| GB9618477D0 (en) * | 1996-09-04 | 1996-10-16 | Univ Leeds | Gene therapy |
| US5858753A (en) * | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| DE19651443A1 (de) * | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
| EP0860445A1 (en) * | 1997-02-18 | 1998-08-26 | Hoechst Aktiengesellschaft | New nucleotide sequences for the cell cycle regulated expression of structural genes |
| ES2200316T3 (es) * | 1997-03-11 | 2004-03-01 | Les Laboratoires Aeterna Inc. | Composiciones para tratar tumores que contienen extractos de cartilago de tiburon y agentes antineoplasticos. |
| CA2284211A1 (en) * | 1997-03-20 | 1998-09-24 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
| US6384203B1 (en) * | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6217900B1 (en) * | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6383746B1 (en) * | 1997-10-23 | 2002-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Functional promoter for CCR5 |
| US6383811B2 (en) * | 1997-12-30 | 2002-05-07 | Mirus Corporation | Polyampholytes for delivering polyions to a cell |
| US6383481B1 (en) * | 1998-03-30 | 2002-05-07 | Japan Immunoresearch Laboratories Co., Ltd. | Method for transplantation of hemopoietic stem cells |
| SK15682000A3 (sk) * | 1998-04-22 | 2001-05-10 | Genvec, Inc. | Účinné čistenie adenovírusu |
| US7052872B1 (en) * | 1999-06-22 | 2006-05-30 | Immunomedics, Inc. | Bi-specific antibodies for pre-targeting diagnosis and therapy |
| US6383794B1 (en) * | 1998-08-24 | 2002-05-07 | Uab Research Foundation | Methods of producing high titer recombinant adeno-associated virus |
| US6197294B1 (en) * | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
| US6380371B1 (en) * | 1998-12-10 | 2002-04-30 | The Regents Of The University Of California | Endoglycan: a novel protein having selectin ligand and chemokine presentation activity |
| US6383753B1 (en) * | 1999-03-31 | 2002-05-07 | Regents Of The University Of Michigan | Yeast mammalian regulators of cell proliferation |
| AU4476600A (en) * | 1999-04-22 | 2000-11-10 | Vanderbilt University | Polymeric encapsulation system promoting angiogenesis |
| US6380382B1 (en) * | 1999-06-30 | 2002-04-30 | Millennium Pharmaceuticals, Inc. | Gene encoding a protein having diagnostic, preventive, therapeutic, and other uses |
| US6380362B1 (en) * | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
| EP1257197A4 (en) * | 2000-02-25 | 2008-07-16 | Health Research Inc | PROCESS FOR TRANSDERMAL SAMPLING OF ANALYTES |
| JP2004506408A (ja) * | 2000-04-26 | 2004-03-04 | イルーシス セラポーティクス，インコーポレーテッド | 二重特異性分子及びその用途 |
| US7560534B2 (en) * | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
| US20050054000A1 (en) * | 2000-08-11 | 2005-03-10 | Stefan Dubel | Fv constructs with an influenceable affinity for a substance that is to be linked |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7148321B2 (en) * | 2001-03-07 | 2006-12-12 | Emd Lexigen Research Center Corp. | Expression technology for proteins containing a hybrid isotype antibody moiety |
| UA78706C2 (en) * | 2001-06-01 | 2007-04-25 | Wyeth Corp | Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer |
| US20030026780A1 (en) * | 2001-07-18 | 2003-02-06 | Hood Leroy E. | Innate immunity mediated methods of treating pathological conditions |
| WO2003033654A2 (en) * | 2001-10-15 | 2003-04-24 | Immunomedics, Inc | Direct targeting binding proteins |
| JP2006502091A (ja) * | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| CN100473664C (zh) * | 2002-12-20 | 2009-04-01 | 拜奥根Idec马萨诸塞公司 | 多价淋巴毒素β受体激动剂及其治疗用途 |
| CN1279056C (zh) * | 2003-06-06 | 2006-10-11 | 马菁 | 肿瘤相关抗原sm5－1的特异性抗体及其应用 |
| US6864837B2 (en) * | 2003-07-18 | 2005-03-08 | Ems Technologies, Inc. | Vertical electrical downtilt antenna |
| JPWO2005018671A1 (ja) * | 2003-08-21 | 2006-10-19 | 協和醗酵工業株式会社 | 癌転移阻害剤 |
| US7736653B2 (en) * | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier |
| US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| US20080181892A1 (en) * | 2004-08-11 | 2008-07-31 | Trubion Pharmaceuticals | Binding Domain Fusion Protein |
| US8034902B2 (en) * | 2005-05-04 | 2011-10-11 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against CD55 and CD59 and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8409577B2 (en) * | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
| NZ581395A (en) * | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
-
2008
- 2008-07-07 JP JP2010515288A patent/JP2010532764A/ja active Pending
- 2008-07-07 CN CN2008801052519A patent/CN101990439A/zh active Pending
- 2008-07-07 WO PCT/US2008/069378 patent/WO2009023386A2/en not_active Ceased
- 2008-07-07 EP EP08827538A patent/EP2167130A2/en not_active Withdrawn
- 2008-07-07 CA CA002691819A patent/CA2691819A1/en not_active Abandoned
- 2008-07-07 AU AU2008287195A patent/AU2008287195A1/en not_active Abandoned
- 2008-07-07 BR BRPI0814060-0A2A patent/BRPI0814060A2/pt not_active IP Right Cessation
- 2008-07-07 US US12/168,875 patent/US20090148447A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010532764A5 (enExample) | ||
| RU2742691C2 (ru) | Cd3-связывающий домен | |
| JP2020184996A5 (enExample) | ||
| JP2022137208A (ja) | ｃ－Ｋｉｔに対するヒト化抗体 | |
| JP2013515508A5 (enExample) | ||
| WO2018027042A1 (en) | Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy | |
| JP2016529882A5 (enExample) | ||
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2009523459A5 (enExample) | ||
| JP7533897B2 (ja) | 融合タンパク質およびその使用 | |
| JP2018510617A5 (enExample) | ||
| JP2017514515A5 (enExample) | ||
| JP2019525728A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| US20230018670A1 (en) | Bispecific GD2 and B7H3 Binding Molecules and Methods of Use | |
| CA3111462A1 (en) | Improved anti-flt3 antigen binding proteins | |
| CA3193273A1 (en) | Methods and compositions to treat autoimmune diseases and cancer | |
| US20250122299A1 (en) | ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| JPWO2023056252A5 (enExample) | ||
| WO2025049818A1 (en) | Tnfr1 antagonists lacking agonist activity and uses thereof | |
| CN118894943A (zh) | 靶向密蛋白的双特异性抗体 | |
| CN118745231A (zh) | 抗ror1和cd3的双特异性抗体及其应用 | |
| RU2021128015A (ru) | Антигенсвязывающие белки, которые связываются с bcma | |
| NZ807450A (en) | Antibodies binding to gprc5d |